Vertex Q2 product revenue $2.20B (+22% YoY); raises FY2022 guidance to $8.6-$8.8B

VERTEX PHARMACEUTICALS INC / MA

2022-Q2 EPS reported $6.09 revenue$4,293,700,000

Product revenues $2.20B, up 22% YoY; TRIKAFTA/KAFTRIO contributed $1.893B.
GAAP diluted EPS $3.13; non-GAAP diluted EPS $3.60.
Raised full-year 2022 product revenue guidance to $8.6-$8.8B from prior $8.4-$8.6B.
Clinical updates: exa-cel (sickle cell/beta thalassemia) and VX-880 (type 1 diabetes) data demonstrate transformative potential.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.